Healthcare provider profile · identity verified

Matthew Yee, MD

Internal Medicine · WAIPAHU, HI · NPI 1346770880

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	974	314
Losartan Potassium	Losartan Potassium	551	180
Amlodipine Besylate	Amlodipine Besylate	530	168
Lisinopril	Lisinopril	388	127
Tamsulosin Hcl	Tamsulosin Hcl	262	78
Metformin Hcl	Metformin Hcl	256	78
Levothyroxine Sodium	Levothyroxine Sodium	245	69
Allopurinol	Allopurinol	199	72
Metoprolol Tartrate	Metoprolol Tartrate	191	62
Jardiance	Empagliflozin	186	59
Metformin Hcl Er	Metformin Hcl	176	63
Atenolol	Atenolol	154	51
Albuterol Sulfate Hfa	Albuterol Sulfate	151	71
Furosemide	Furosemide	150	59
Simvastatin	Simvastatin	145	51
Glipizide	Glipizide	117	41
Gabapentin	Gabapentin	113	36
Oxycodone Hcl	Oxycodone Hcl	113	27
Hydrochlorothiazide	Hydrochlorothiazide	111	40
Metoprolol Succinate	Metoprolol Succinate	106	40
Glipizide Er	Glipizide	104	36
Pradaxa	Dabigatran Etexilate Mesylate	103	28
Clopidogrel	Clopidogrel Bisulfate	97	30
Finasteride	Finasteride	93	27
Potassium Chloride	Potassium Chloride	92	26
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	85	29
Arexvy	Rsvpref3 Antigen/As01e/Pf	79	79
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	79	25
Rosuvastatin Calcium	Rosuvastatin Calcium	78	23
Triamcinolone Acetonide	Triamcinolone Acetonide	78	49
Alendronate Sodium	Alendronate Sodium	76	24
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	70	23
Pravastatin Sodium	Pravastatin Sodium	70	22
Carvedilol	Carvedilol	66	22
Humulin N	Insulin Nph Human Isophane	64	26
Tenivac	Tetanus-Diphtheria Toxoids/Pf	61	61
Alvesco	Ciclesonide	58	25
Baclofen	Baclofen	57	19
Pantoprazole Sodium	Pantoprazole Sodium	56	21
Wixela Inhub	Fluticasone Propion/Salmeterol	56	20
Prednisone	Prednisone	53	35
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	52	suppressed
Colchicine	Colchicine	50	20
Omeprazole	Omeprazole	49	19
Xarelto	Rivaroxaban	44	15
Warfarin Sodium	Warfarin Sodium	43	12
Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	42	17
Liraglutide	Liraglutide	41	11
Spironolactone	Spironolactone	41	15
Trazodone Hcl	Trazodone Hcl	41	23
Ezetimibe	Ezetimibe	39	14
Ketoconazole	Ketoconazole	38	21
Mirtazapine	Mirtazapine	38	13
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	37	13
Meloxicam	Meloxicam	37	18
Terazosin Hcl	Terazosin Hcl	37	suppressed
Tramadol Hcl	Tramadol Hcl	37	14
Insulin Syringe	Syring-Needl,disp,insul,0.3 Ml	35	11
Hydralazine Hcl	Hydralazine Hcl	34	suppressed
Victoza 3-Pak	Liraglutide	32	suppressed
Cephalexin	Cephalexin	31	25
Clobetasol Propionate	Clobetasol Propionate	31	15
Pregabalin	Pregabalin	31	11
Azithromycin	Azithromycin	30	25
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	28	12
Nifedipine Er	Nifedipine	27	suppressed
Alprazolam	Alprazolam	26	14
Montelukast Sodium	Montelukast Sodium	26	suppressed
Sertraline Hcl	Sertraline Hcl	26	suppressed
Shingrix	Varicella-Zoster Ge/As01b/Pf	26	26
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	25	12
Ibuprofen	Ibuprofen	25	14
Naproxen	Naproxen	25	15
Cefpodoxime Proxetil	Cefpodoxime Proxetil	24	24
Mupirocin	Mupirocin	24	13
Nortriptyline Hcl	Nortriptyline Hcl	24	suppressed
Levetiracetam	Levetiracetam	22	suppressed
Victoza 2-Pak	Liraglutide	22	suppressed
Fluticasone Propionate	Fluticasone Propionate	21	15
Lorazepam	Lorazepam	21	13
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	20	20
Duloxetine Hcl	Duloxetine Hcl	20	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	19	suppressed
Sodium Chloride	Sodium Chloride Irrig Solution	19	suppressed
Eliquis	Apixaban	18	suppressed
Humulin N Kwikpen	Insulin Nph Human Isophane	18	suppressed
Lactulose	Lactulose	18	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	18	suppressed
Ciclopirox	Ciclopirox	17	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	17	suppressed
Insulin Syringe	Syringe And Needle,insulin,1ml	17	suppressed
Propranolol Hcl	Propranolol Hcl	17	suppressed
Acarbose	Acarbose	16	suppressed
Humulin R	Insulin Regular, Human	16	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	16	suppressed
Torsemide	Torsemide	16	suppressed
Donepezil Hcl	Donepezil Hcl	14	suppressed
Humalog Kwikpen U-100	Insulin Lispro	14	suppressed
Hydrocortisone	Hydrocortisone	14	suppressed
Ipratropium Bromide	Ipratropium Bromide	14	suppressed
Latanoprost	Latanoprost	14	suppressed
Lidocaine	Lidocaine	14	suppressed
Ondansetron Odt	Ondansetron	14	suppressed
Paroxetine Hcl	Paroxetine Hcl	14	suppressed
Digoxin	Digoxin	13	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	13	11
Lovastatin	Lovastatin	13	suppressed
Potassium Citrate Er	Potassium Citrate	13	suppressed
Verapamil Er	Verapamil Hcl	13	suppressed
Dabigatran Etexilate	Dabigatran Etexilate Mesylate	12	12
Morphine Sulfate	Morphine Sulfate	12	suppressed
Nystatin	Nystatin	12	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	12	12
Single Use Swab	Alcohol Antiseptic Pads	12	suppressed
Betamethasone Dipropionate	Betamethasone Dipropionate	11	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	11	suppressed
Hydromorphone Hcl	Hydromorphone Hcl	11	suppressed
Spiriva Respimat	Tiotropium Bromide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error